Testing a Drug to Help with Sexual Side Effects from Breast Cancer Treatment
Treatments studied
Part of Cancer, Mental health, Skin clinical trials.
This study tests whether a medication called bupropion can help women with hormone receptor-positive breast cancer who are taking aromatase inhibitors (drugs that block estrogen) but experiencing low sexual desire as a side effect. The goal is to see if this approach improves both tolerance to the cancer medication and quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with early-stage hormone receptor-positive breast cancer (stage I–III) that has been surgically removed
- You have completed all planned cancer treatments (surgery, radiation, and/or chemotherapy if needed) before starting this study
- You are experiencing low sexual desire as a side effect of aromatase inhibitor treatment
- You are able to swallow oral medication and willing to return to the clinic for follow-up visits
- You are not pregnant, not breastfeeding, and willing to use birth control during the study and for 30 days after it ends
- You do not have a history of certain mental health conditions, seizures, or eating disorders
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing how well a short course of hormone-blocking pills (endocrine therapy) works before surgery in women with early-stage hormone receptor-positive HER2-negative breast cancer. The goal is to understand what makes some cancers resistant to these treatments.
This trial tests whether switching to a different aromatase inhibitor or using standard treatments works better for managing side effects in breast cancer survivors. It aims to help you stay on hormone therapy longer with fewer discomforts.
This study tests whether a special anti-inflammatory diet can help reduce side effects in breast cancer survivors who are taking aromatase inhibitors after menopause. You would be randomly assigned to either follow the diet for 6 months or continue your usual diet, and your health will be monitored.
This Phase 3 trial checks whether adding chemotherapy after standard hormone-blocking treatment works better for some premenopausal women with early-stage, ER-positive, HER2-negative breast cancer. It targets patients with limited lymph node spread and a lower-to-intermediate tumor “recurrence” risk score.
This trial tests if adding a targeted drug (CDK4/6 inhibitor) to hormone therapy works better than hormone therapy alone for women with a certain type of breast cancer (HR+/HER2-). The study measures the activity of tumor cells (Ki-67) to help decide treatment.
This trial tests a new oral drug (HRS-8080) against standard hormone therapy for women with intermediate- or high-risk early breast cancer who have already completed 2 to 5 years of hormone treatment. It aims to see if the new drug can reduce the risk of cancer coming back.
Hear when a new Early-stage Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.